for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sensei Biotherapeutics Inc

SNSE.O

Latest Trade

11.99USD

Change

0.13(+1.10%)

Volume

56,001

Today's Range

11.76

 - 

12.16

52 Week Range

9.05

 - 

26.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.86
Open
12.09
Volume
56,001
3M AVG Volume
2.88
Today's High
12.16
Today's Low
11.76
52 Week High
26.50
52 Week Low
9.05
Shares Out (MIL)
30.59
Market Cap (MIL)
366.76
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Sensei Biotherapeutics Announces Clinical Data From Ongoing Phase 1/2 Combination Trial Of SNS-301 In Patients With Squamous Cell Carcinoma Of The Head And Neck

Sensei Biotherapeutics Posts Qtrly Loss Per Share $0.42

Sensei Biotherapeutics Reports Full Year 2020 Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sensei Biotherapeutics Inc

Sensei Biotherapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the discovery and development of therapies with focus on treatments for cancer. Its ImmunoPhage platform is a self-adjuvanted and differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. The Company is engineering its ImmunoPhage product candidates to directly target antigen presenting cells (APCs) and modulate the tumor microenvironment (TME) through the targeted use of nanobodies which enhances therapeutic activity. SNS-301 is an ImmunoPhage product candidate that the Company is developing as a treatment for locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN). It also develops ImmunoPhage candidate, SNS-401, for the treatment of Merkel cell carcinoma (MCC). The Company is also engaged in developing a monoclonal antibody (mAb) therapy.

Industry

Business Services

Contact Info

620 Professional Drive

GAITHERSBURG, MD

20879

United States

+1.240.2438000

https://www.senseibio.com/

Key Stats

1.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020

0.0K

2021(E)

0.0K
EPS (USD)

2020

-12.530

2021(E)

-1.296
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.14
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.33
LT Debt To Equity (MRQ)
0.33
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up